Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 15,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer directly owned 577,133 shares of the company’s stock, valued at $85,785,049.12. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, August 3rd, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00.
• On Wednesday, July 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $149.61 on Thursday. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business has a 50 day simple moving average of $135.66 and a 200 day simple moving average of $136.45. The company has a market capitalization of $185.51 billion, a PE ratio of -56.03 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The business’s revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s payout ratio is currently -122.85%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Gilead Sciences by 12,498.3% during the 2nd quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company’s stock worth $30,469,248,000 after purchasing an additional 239,254,365 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $15,393,785,000. Norges Bank bought a new position in shares of Gilead Sciences in the fourth quarter valued at $2,617,152,000. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the second quarter valued at $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in Gilead Sciences during the second quarter worth $918,387,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Rothschild & Co Redburn lowered their price target on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Daiwa Securities Group dropped their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.